The volume procurement was implemented only in January, and Lipitor, Luohuoxi and Plavi were out of the top 20 in Fujian!

Reading the changes of Fujian market pattern provides an excellent sample for the industry to observe the market changes after volume purchasing On August 6, Fujian announced the top 20 drug sales in June 2019 June is the first month for Fujian Province to follow up with volume purchase The change of Fujian market pattern provides an excellent sample for the industry to observe the market change after volume purchase All the original research drugs of the winning varieties have been out of the market The first Chinese patent drugs listed are new changes brought by volume purchase According to the plan of the state health insurance bureau, the volume purchase of these 25 varieties will be promoted nationwide in September, and the market pattern nationwide can be expected to change Interesting learned that in order to actively respond to market changes, Pfizer actively seeks new opportunities From August 1, the original 3500 cardiovascular team began to promote new products and become a national agent of a domestic innovative drug On May 21, the general office of Fujian provincial government printed and distributed the implementation plan for Fujian Province to comprehensively implement and follow up the pilot work of national organization of centralized drug purchase and use, which made it clear that the whole province followed up the pilot work of national organization of centralized drug purchase and use It is stipulated that public medical institutions in Fujian Province will start to purchase relevant drugs (25 varieties) from June 1, and patients can purchase drugs according to the selected price from June 3 The author has noticed that only one month has passed since the implementation of volume procurement, and the original market pattern has begun to change: the top 20 Pfizer products, including atorvastatin (Lipitor), amlodipine besylate (loxorubicin), and Sanofi's clopidogrel bisulfate (Plavix), have all fallen out of the top 20 According to the sales ranking of Fujian Province, Pfizer's Lipitor has occupied the top three drugs in sales for a long time, and the top 10 varieties of luohuoxi Although clopidogrel ranks slightly lower, it also ranks in the top 20 products According to the specific sales situation, according to the public inquiry information of Fujian pharmaceutical and machinery platform, the procurement records of atorvastatin with a volume of 20 mg * 7 of Jialin pharmaceutical in the past month were 626 The procurement record of Pfizer Lipitor in the past month is 559, which is lower than that of the winning drugs However, considering that the winning price of Jialin pharmaceutical is only 6.6 yuan, the price of Pfizer's products with the same product specification will be reduced to 42.77 yuan after purchasing in volume, which is several times the price of the winning varieties If there is a small gap in the procurement records, it should be difficult for the procurement amount of the winning drugs to exceed the original research drugs In addition, according to the information released by Fujian pharmaceutical machinery purchase platform, the purchase price of the selected products in Jialin is not 6.6 yuan, but 39.5 yuan Therefore, I think the above procurement records are for reference only, and more specific procurement information may need to be further updated by Fujian procurement platform This is not the only change brought about by the implementation of volume purchasing for the first time The drug with the highest sales volume is trastuzumab for injection from Genentech Inc (Shanghai Roche Pharmaceutical Co., Ltd.), which is the first time this year that the drug has topped the list The indication of the product is metastatic mammary gland This is also one of 36 winning drugs in the health insurance negotiation held by the Ministry of human resources and social security in 2017 last year Secondly, for the first time, traditional Chinese medicine products appear in the list The sales amount of Shexiang Baoxin Pill of Shanghai Hehuang Pharmaceutical Co., Ltd has become the eighth place in the sales list According to the public information, the drug is a Chinese patent medicine and prescription medicine, which belongs to class a medical insurance drug Its main indications are: for the chest obstruction caused by qi stagnation and blood stasis, the symptoms are pain in the precordial area and immobility; for the angina pectoris and myocardial infarction caused by myocardial ischemia, the above syndromes are mainly used for the chest obstruction caused by qi stagnation and blood stasis, the symptoms are pain in the precordial area and immobility; for the angina pectoris and angina pectoris caused by myocardial ischemia Myocardial infarction This is also the first time that Chinese patent medicine appears in the list of sales amount of drugs purchased by sunshine with joint price limit in Fujian Province After volume purchase, Chinese patent medicine has been claiming to welcome good news and actively engaged with agents, which seems to be proved by Fujian sales ranking But there are also senior agents that say that Chinese patent medicine is also a pit The main reason is that there are TCM departments in TCM hospitals, and the profit of opening decoction pieces is much more than that of opening Chinese patent medicine On the same day, Xi'an, one of the 11 cities, issued a notice on the work of increasing the quantity of the selected drugs in the volume procurement According to the notice, the national agreed quantity of procurement and Xi'an prepared quantity of procurement have exceeded expectations After research, it was decided to start the submission work of increasing purchase volume of selected drugs in Xi'an Previously, in the pilot city in Liaoning Province, after the increase of purchase volume, the payment collection cycle turned into a six-month accounting period plus six-month bill exchange, which made the distributors complain incessantly In the notice, Xi'an city specially pointed out that the incremental payment collection reported this time was carried out in accordance with the original payment collection method of volume purchase According to the plan of the state health insurance bureau, the national promotion of the purchase of these 25 varieties with volume will be completed in September this year, and the market pattern will be changed soon So what about Pfizer's 3500 cardiovascular promotion team? Is the original research drug of other winning varieties abandoned or continue to compete for the original market? Interesting learned that Pfizer has also found new opportunities in addition to Pfizer's announcement of the establishment of a joint venture with international generics giant Mai LAN At present, Pfizer has signed the national agency right of the thrombolytic new drug mingfule (teneplase) under Guangzhou Mingkang Bioengineering Co., Ltd., a domestic innovative pharmaceutical company From August 1, Pfizer's team has fully promoted the product According to the public information, mingfule is the first third generation thrombolytic drug in China with independent intellectual property rights and the approval of listing It is the only thrombolytic drug that can be used for single intravenous injection at present and approved for listing in 2015 It is an exclusive variety in China It is clinically used for thrombolytic therapy of acute myocardial infarction It can save lives in one shot for this major disease of acute myocardial infarction It is understood that after the listing of mingfule, agents have been responsible for promoting sales, but the market has not done well "After Pfizer takes over, what Mingkang biology needs to consider in the future is whether the capacity can be supplied." Wang Peng, vice president of yaomaitong, commented He said that mingfule and Pfizer's product strategy are very consistent The cardiovascular field has always been Pfizer's strong point Mingfule is an emergency medicine for stroke, which has high clinical value, high unit price and can support a team.